Go to Health Care Provider version
| Diagnosis | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Study Status | Open |
| Phase | I/II |
| Age | 18 Years and older | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Drug: CFI-400945 (oral)
Arm 2A only: Azacitidine (IV)
|
| Last Posted Update | 2024-04-09 |
| ClinicalTrials.gov # | NCT04730258 |
International Sponsor
Treadwell Therapeutics, IncPrincipal Investigators for Canadian Sites
Princess Margaret Cancer CentreCentres
Medical contact
N/A
Social worker/patient navigator contact
N/A
Clinical research contact
N/A
Study Description
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Inclusion Criteria
- Patients must be >18 years of age
- Patients must have a qualifying diagnosis of Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) that has come back or not responded to other treatment
- Have acceptable laboratory screening results within certain limits
- Be able to carry out light daily work with little/no restriction
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team
